NCNathan P. Crilly

Nathan P. Crilly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathan P. Crilly has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Management of Helicobacter Infection in Captive Baboons ( Papio anubis and Papio hamadryas ), and Isolation and Molecular Characterization of Three Novel Helicobacter Species

    by Isabel A. Jimenez, Courtney Lunger, Marcus J. Crim, Shannon L. Primm, Anthony Mannion, Nathan P. Crilly, Lydia M. Hopper, Lindsey G. Thurman, Linnette L. Vasquez, Cory Brayton, et al.

    Background: Helicobacter spp. are gastric or enterohepatic bacteria that can be commensal, opportunistic, or pathogenic. Few studies have evaluated Helicobacter spp. in baboons. Methods: Twenty‐seven captive baboons were surveyed for Helicobacter spp. by fecal PCR, and a subset evaluated by culture. Nine baboons were treated with oral “triple therapy” with clarithromycin (10 mg/kg), amoxicillin (10 mg/kg), and omeprazole (20 mg) once daily for 10 days. Results: All baboons were positive for Helicobacter spp., including H. macacae (78%), H. suis (19%), and H. pylori (15%). Three novel Helicobacter species were identified by whole genomic sequencing, for which we propose the names Helicobacter papionis , H. simiae , and H. papionifaecis. Treatment was safe and effective for H. pylori , H. suis , and H. macacae , but did not eliminate the novel Helicobacter spp. Conclusions: Species‐specific assays should guide treatment of Helicobacter spp. infections in baboons. Further epidemiologic studies are needed to inform clinical management.

  • Open Access

    A murine model of Trypanosoma brucei- induced myocarditis and cardiac dysfunction

    by Nathan P. Crilly, Marcelle Dina Zita, Alexander K. Beaver, Polina Sysa-Shah, Aashik Bhalodia, Kathy Gabrielson, Luigi Adamo, Monica R. Mugnier

    Trypanosoma brucei is a protozoan parasite that causes human and animal African trypanosomiases (HAT and AAT). Cardiac symptoms are commonly reported in HAT patients, and intracardiac parasites with accompanying myocarditis have been observed in both natural hosts and animal models of T. brucei infection. Despite the importance of T. brucei as a cause of cardiac dysfunction and the dramatic socioeconomic impact of African trypanosomiases in sub-Saharan Africa, there are currently no reproducible murine models of T. brucei- associated cardiomyopathy. We present the first clinically relevant, reproducible murine model of cardiac dysfunction in chronic T. brucei infection. Similar to humans, mice showed histological evidence of myocarditis and elevation of serum NT-proBNP with electrocardiographic abnormalities. Serum NT-proBNP levels were elevated prior to the development of severe ventricular dysfunction. On flow cytometry, myocarditis was associated with an increase of most myocardial immune cell populations, including multiple T cell and macrophage subsets, corroborating the notion that T. brucei- associated cardiac damage is an immune-mediated event. This novel mouse model represents a powerful and practical tool to investigate the pathogenesis of T. brucei -mediated heart damage and supports the development of therapeutic options for T. brucei -associated cardiac disease. In characterizing this model, we provide evidence that T. brucei causes cardiac disease, and we suggest that immunopathology is an important contributor to cardiac pathology. Along with other recent studies, our work demonstrates the importance of extravascular spaces, including the heart, for T. brucei pathogenesis. IMPORTANCE: African trypanosomiasis is a neglected tropical disease affecting both people and cattle, which represents a major public health problem in sub-Saharan Africa with an enormous socioeconomic impact. Cardiac disease represents an underappreciated clinical manifestation of African trypanosomiasis that may lead to lifelong illness despite successful treatment of infection. However, this aspect of African trypanosomiasis remains poorly understood, partially due to a lack of well-characterized and practical animal models. In this study, we present the development and characterization of a novel, reproducible, and cost-effective mouse model of cardiac dysfunction in African trypanosomiasis. We demonstrate that this model recapitulates major features of cardiac dysfunction in natural infection, including the presence of parasites in the cardiac interstitial spaces, alterations of cardiac biomarkers, and functional changes. This model represents a resource to support the understanding of cardiac complications of trypanosomiasis and the development of new therapies to prevent and treat cardiac involvement in African trypanosomiasis.


  • Open Access

    A murine model of Trypanosoma brucei- induced myocarditis and cardiac dysfunction

    by Nathan P. Crilly, Marcelle Dina Zita, Alexander K. Beaver, Polina Sysa-Shah, Aashik Bhalodia, Kathy Gabrielson, Luigi Adamo, Monica R. Mugnier

    Trypanosoma brucei is a protozoan parasite that causes human and animal African trypanosomiases (HAT and AAT). Cardiac symptoms are commonly reported in HAT patients, and intracardiac parasites with accompanying myocarditis have been observed in both natural hosts and animal models of T. brucei infection. Despite the importance of T. brucei as a cause of cardiac dysfunction and the dramatic socioeconomic impact of African trypanosomiases in sub-Saharan Africa, there are currently no reproducible murine models of T. brucei- associated cardiomyopathy. We present the first clinically relevant, reproducible murine model of cardiac dysfunction in chronic T. brucei infection. Similar to humans, mice showed histological evidence of myocarditis and elevation of serum NT-proBNP with electrocardiographic abnormalities. Serum NT-proBNP levels were elevated prior to the development of severe ventricular dysfunction. On flow cytometry, myocarditis was associated with an increase of most myocardial immune cell populations, including multiple T cell and macrophage subsets, corroborating the notion that T. brucei- associated cardiac damage is an immune-mediated event. This novel mouse model represents a powerful and practical tool to investigate the pathogenesis of T. brucei -mediated heart damage and supports the development of therapeutic options for T. brucei -associated cardiac disease.

  • Open Access

    Extravascular spaces are the primary reservoir of antigenic diversity in Trypanosoma brucei infection

    by Alexander K. Beaver, Zhibek Keneskhanova, Raúl O. Cosentino, Brian L. Weiss, Erick O. Awuoche, Gretchen M. Smallenberger, Gracyn Y. Buenconsejo, Nathan P. Crilly, Jaclyn E. Smith, Jill M.C. Hakim, et al.

    Summary paragraph: The protozoan parasite Trypanosoma brucei evades clearance by the host immune system through antigenic variation of its dense variant surface glycoprotein (VSG) coat, periodically “switching” expression of the VSG using a large genomic repertoire of VSG-encoding genes 1–6 . Recent studies of antigenic variation in vivo have focused near exclusively on parasites in the bloodstream 4,7,8 , but research has shown that many, if not most, parasites reside in the interstitial spaces of tissues 9–13 . We sought to explore the dynamics of antigenic variation in extravascular parasite populations using VSG-seq 7 , a high-throughput sequencing approach for profiling VSGs expressed in populations of T. brucei . Here we show that tissues, not the blood, are the primary reservoir of antigenic diversity during both needle- and tsetse bite-initiated T. brucei infections, with more than 75% of VSGs found exclusively within extravascular spaces. We found that this increased diversity is correlated with slower parasite clearance in tissue spaces. Together, these data support a model in which the slower immune response in extravascular spaces provides more time to generate the antigenic diversity needed to maintain a chronic infection. Our findings reveal the important role that extravascular spaces can play in pathogen diversification.


  • Open Access

    Thinking outside the blood: Perspectives on tissue-resident Trypanosoma brucei

    by Nathan P. Crilly, Monica R. Mugnier

    Trypanosoma brucei is a protozoan parasite that causes human and animal African trypanosomiases (HAT and AAT). In the mammalian host, the parasite lives entirely extracellularly, in both the blood and interstitial spaces in tissues. Although most T. brucei research has focused on the biology of blood- and central nervous system (CNS)-resident parasites, a number of recent studies have highlighted parasite reservoirs in the dermis and adipose tissue, leading to a renewed interest in tissue-resident parasite populations. In light of this renewed interest, work describing tissue-resident parasites can serve as a valuable resource to inform future investigations of tissue-resident T. brucei. Here, we review this body of literature, which describes infections in humans, natural hosts, and experimental animal models, providing a wealth of information on the distribution and biology of extravascular parasites, the corresponding immune response in each tissue, and resulting host pathology. We discuss the implications of these studies and future questions in the study of extravascular T. brucei.


  • Open Access

    The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex

    by Nathan P. Crilly, Samuel K. Ayeh, Petros C. Karakousis

    Mycobacterium avium complex (MAC) is an increasingly important cause of morbidity and mortality, and is responsible for pulmonary infection in patients with underlying lung disease and disseminated disease in patients with AIDS. MAC has evolved various virulence strategies to subvert immune responses and persist in the infected host. Current treatment for MAC is challenging, requiring a combination of multiple antibiotics given over a long time period (for at least 12 months after negative sputum culture conversion). Moreover, even after eradication of infection, many patients are left with residual lung dysfunction. In order to address similar challenges facing the management of patients with tuberculosis, recent attention has focused on the development of novel adjunctive, host-directed therapies (HDTs), with the goal of accelerating the clearance of mycobacteria by immune defenses and reducing or reversing mycobacterial-induced lung damage. In this review, we will summarize the evidence supporting specific adjunctive, HDTs for MAC, with a focus on the repurposing of existing immune-modulatory agents targeting a variety of different cellular pathways. We also highlight areas meriting further investigation.